Preferred Label : Nectin-4-directed TLR8 Agonist SBT6290;
NCIt synonyms : Anti-nectin-4 Monoclonal Antibody-TLR8 Agonist Conjugate SBT6290; TLR8 Agonist-nectin-4-directed Monoclonal Antibody Conjugate SBT6290; Nectin-4-directed TLR8 ImmunoTAC SBT6290; ImmunoTAC SBT6290;
NCIt definition : An immunotherapeutic composed of a monoclonal antibody directed against the cell surface
adhesion molecule and tumor-associated antigen (TAA) nectin-4 (PVRL4) conjugated to
a Toll-like receptor 8 (TLR8; CD288) agonist, with potential immunostimulating and
antineoplastic activities. Upon administration of the nectin-4-directed TLR8 agonist
SBT6290, the anti-nectin-4 monoclonal antibody targets and binds to nectin-4 expressed
on tumor cells, thereby localizing the TLR8 agonist directly to the tumor site. In
turn, the TLR8 agonist moiety binds to TLR8 expressed on myeloid cells within the
tumor microenvironment (TME). This activates myeloid cells, including tumor-associated
macrophages (TAMs), myeloid cell-derived suppressive cells (MDSCs), and conventional
dendritic cells (cDCs), and may lead to the activation of nuclear factor NF-kappa-B,
the production of pro-inflammatory cytokines and chemokines, macrophage-induced tumor
cell killing, inflammasome activation, the activation of cytolytic natural killer
(NK) cells and neutrophils, and the induction of a T-helper cell type 1 (Th1)-weighted
anti-tumor immune response. It also reverses the suppression of senescent naive and
tumor-specific T-cells, and enhances the anti-tumor cytotoxic T-lymphocyte (CTL) immune
response. TLR8, like other TLRs, recognizes pathogen-associated molecular patterns
(PAMPs) and plays a key role in innate and adaptive immunity. Nectin-4, a TAA belonging
to the nectin family, is overexpressed in a variety of cancers, but has a restricted
distribution in normal tissue.;
Molecule name : SBT 6290; SBT-6290;
NCI Metathesaurus CUI : CL1779262;
Origin ID : C187020;
UMLS CUI : C5667086;
Semantic type(s)
- concept_is_in_subset
- has_target
